Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2006;37:2957-2962
Published online before print October 26, 2006, doi: 10.1161/01.STR.0000249054.96644.c6
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
37/12/2957    most recent
01.STR.0000249054.96644.c6v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kent, D. M.
Right arrow Articles by Hacke, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kent, D. M.
Right arrow Articles by Hacke, W.
Related Collections
Right arrow Thrombolysis
Right arrow Acute Cerebral Infarction
Right arrow Emergency treatment of Stroke
Right arrow Fibrinolysis
Right arrowRelated Article

(Stroke. 2006;37:2957.)
© 2006 American Heart Association, Inc.


Original Contributions

The Stroke–Thrombolytic Predictive Instrument

A Predictive Instrument for Intravenous Thrombolysis in Acute Ischemic Stroke

David M. Kent, MD, MS; Harry P. Selker, MD, MSPH; Robin Ruthazer, MPH; Erich Bluhmki, PhD Werner Hacke, MD

From Institute for Clinical Research and Health Policy Studies and Department of Medicine (D.M.K., H.P.S., R.R.), Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Mass; Boehringer Ingelheim (E.B.), Ingelheim, Germany; Department of Neurology (W.H.), University of Heidelberg, Heidelberg, Germany.

Correspondence to David M. Kent, MD, MS, Institute for Clinical Research and Health Policy Studies, Tufts-New England Medical Center, 750 Washington St, #63, Boston, MA, 02111. E-mail Dkent1{at}tufts-nemc.org

Background and Purpose— Many patients with ischemic stroke eligible for recombinant tissue plasminogen activator (rt-PA) are not treated in part because of the risks and benefits perceived by treating physicians. Therefore, we aimed to develop a Stroke-Thrombolytic Predictive Instrument (TPI) to aid physicians considering thrombolysis for stroke.

Methods— Using data from 5 major randomized clinical trials (n=2184) testing rt-PA in the 0- to 6-hour window, we developed logistic regression equations using clinical variables as potential predictors of a good outcome (modified Rankin Scale score ≤1) and of a catastrophic outcome (modified Rankin Scale score ≥5), with and without rt-PA. The models were internally validated using bootstrap re-sampling.

Results— To predict good outcome, in addition to rt-PA treatment, 7 variables significantly affected prognosis and/or the treatment-effect of rt-PA: age, diabetes, stroke severity, sex, previous stroke, systolic blood pressure, and time from symptom onset. To predict catastrophic outcome, only age, stroke severity, and serum glucose were significant; rt-PA treatment was not. For patients treated within 3 hours, the median predicted probability of a good outcome with rt-PA was 42.9% (interquartile range [IQR]=18.6% to 64.7%) versus 25.3% (IQR=9.8% to 46.2%) without rt-PA; the median predicted absolute benefit was 12.5% (IQR=5.1% to 21.0%). The median probability for a catastrophic outcome, with or without, rt-PA was 15.2% (IQR=8.0% to 31.2%). The area under the receiver-operator characteristic curve was 0.788 for the model predicting good outcome and 0.775 for the model predicting bad outcome.

Conclusions— The Stroke-TPI predicts good and bad functional outcomes with and without thrombolysis. Incorporated into a usable tool, it may assist in decision-making.


Key Words: acute care • acute Rx • acute stroke • clinical decision support • emergency medicine • predictive models • thrombolysis • thrombolytic Rx


Related Article:

The Stroke-Thrombolytic Predictive Instrument Provides Valid Quantitative Estimates of Outcome Probabilities and Aids Clinical Decision-Making
Bart M. Demaerschalk
Stroke 2006 37: 2865-2866. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M Uyttenboogaart, R E Stewart, P C Vroomen, G-J Luijckx, and J De Keyser
Utility of the stroke-thrombolytic predictive instrument
J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1079 - 1081.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Yong and M. Kaste
Association of Characteristics of Blood Pressure Profiles and Stroke Outcomes in the ECASS-II Trial
Stroke, February 1, 2008; 39(2): 366 - 372.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
D. M. Kent, H. P. Selker, R. Ruthazer, E. Bluhmki, and W. Hacke
Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?
Stroke, December 1, 2006; 37(12): 2963 - 2969.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
B. M. Demaerschalk
The Stroke-Thrombolytic Predictive Instrument Provides Valid Quantitative Estimates of Outcome Probabilities and Aids Clinical Decision-Making
Stroke, December 1, 2006; 37(12): 2865 - 2866.
[Full Text] [PDF]